Net revenues, cost of product sales and gross profit for each of our commercial products were as follows (in thousands):

	Three Months Ended June 30,
	Remodulin		Tyvaso		Adcirca		Orenitram		Total
2015
Net revenues	$	135,957	$	115,841	$	68,081	$	25,870	$	345,749
Cost of product sales(1)	3,372		4,548		3,906		1,784		13,610

Gross profit	$	132,585	$	111,293	$	64,175	$	24,086	$	332,139


2014
Net revenues	$	138,152	$	121,227	$	55,318	$	6,632	$	321,329
Cost of product sales	14,381		18,744		3,389		2,195		38,709

Gross profit	$	123,771	$	102,483	$	51,929	$	4,437	$	282,620

	Six Months Ended June 30,
	Remodulin		Tyvaso		Adcirca		Orenitram		Total
2015
Net revenues	$	282,238	$	229,221	$	113,451	$	46,756	$	671,666
Cost of product sales(1)	9,346		12,419		6,687		5,472		33,924

Gross profit	$	272,892	$	216,802	$	106,764	$	41,284	$	637,742


2014
Net revenues	$	274,259	$	228,313	$	96,678	$	6,632	$	605,882
Cost of product sales	27,607		33,198		5,982		2,522		69,309

Gross profit	$	246,652	$	195,115	$	90,696	$	4,110	$	536,573

(1)

Cost of product sales for the three and six months ended June 30, 2015 excludes costs related to the production of inventory for Unituxin, as this product was not approved by the FDA until March 2015. Sales of Unituxin commenced in the third quarter of 2015.